{
  "report_rows": [
    {
      "kpi": "Opdivo Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.55B vs. cons $2.461B (Visible Alpha, Jul 29, 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Eliquis Revenue (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$3.85B vs. cons $3.968B (Visible Alpha, Jul 29, 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$11.80B vs. cons $11.73B (Visible Alpha, Jul 29, 2026)",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Revenue (full year)",
      "prediction": "LOWER",
      "answer": "guide mid ~$47.0B vs. cons $47.45B (Visible Alpha, Jul 29, 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Non-GAAP EPS (full year)",
      "prediction": "BETTER",
      "answer": "guide mid ~$6.53 vs. cons $6.34 (Visible Alpha, Jul 29, 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Qualitative: Opdivo inventory normalization commentary",
      "prediction": "LOWER",
      "answer": "Confirm partial normalization with cautious language vs. consensus expectation of full recovery",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.0,
  "day5_path": "STABILIZE",
  "day5_rationale": "STABILIZE \u2014 EPS guide raise offsets revenue estimate drift lower; Opdivo normalization narrative supports the stock but Eliquis trajectory concerns and revenue guide top below consensus cap upside",
  "day5_confidence": "MEDIUM"
}